Recruited by NJ State PhRMA Task Force and appointed by multiple governors to oversee appropriate drug utilization, identify issues / trends, and take actions in the form of edits / protocols and individual physician contacts, and communicate information through newsletters to ensure patient safety and safe prescribing initiatives. Consult with the State on individual projects, as well as 340b utilization, pricing, analysis, and reimbursement.Selected accomplishments: ♦ Saved the State of New Jersey millions of dollars by independently consulting with State pharmacy administrator employees regarding 340b pricing, concepts, regulations, and programs designed to reduce upfront expenditures of the Medicaid pharmacy program. ♦ Conducted Oxycodone and Atrial Fibrillation drug utilization and protocol reviews, comparison of colony-stimulation factors and anti-migraine agents, and prepared a top drugs report in first five months of 2015 to ensure appropriate utilization, patient safety, and consistency across protocol guidelines, and address short- / long-term affects of products.♦ Performed low dose quetiapine utilization review, protocol review / comparisons for Lidoderm, Zyvox, Mepron, ADHD drugs, Sovaldi, Ranexa, low molecular weight heparin, inhaled corticosteroid / LABA combination products, and developed “Acute Pain Treatment Options” newsletter in 2014.

Accepted to conduct analyses, develop internal practices, and develop, implement, and evaluate a public health prevention program.• Conducted community needs analysis for health services• Employed evidence-based practices to design a population-based intervention• Developed culturally appropriate communication strategy tailored to target population• Used best practices of health promotion to implement and evaluate a health screening program• Exceeded all stated goals- increase attendance, PCP utilization, program satisfaction

Consult with marketing agencies, medical device manufacturers, pharmaceutical companies, and burgeoning pharmaceutical companies to develop strategic plans and tactics to meet their needs and those of their clients or primary stakeholders. • Supporting mid-size marketing agency to expand their managed markets function and serving as consultant on several projects.• Working with global company that provides real world insights into the healthcare market, to improve their US marketing • Advised Amneal Pharmaceuticals on Medicare reimbursement pricing and practices for their newly approved drug and created strategy for Amneal to gain approval by the national Medicare Administrative Contractors • Developed strategy and tactics of a national campaign for DePuy Synthes to provide strategic guidance to key stakeholders in support of their achievement of quality, outcomes, and financial goals within a new Medicare reimbursement model for joint replacement (CJR)• Researched and developed content for DePuy Synthes by creating a series of educational leave behinds on payer practices and health care reform in select patient populations, informing physicians and sales force on relevant payer practices

Recruited to provide the strategic leadership for managed markets insights, strategies, and tactics for bio-pharmaceutical clients including AbbVie, Alkermes, GSK, Janssen Therapeutics, Boehringer, Synergy, etc. • Served as the Mosaic/FCB in-house resource on all matters pertaining to managed markets including current trends and future directions related to access and reimbursement, organized customers, channel developments (e.g. ACO, IDNs, SPP, etc.), pharmacy and medical benefit designs, ACA and its implications• Developed strategic response and presentation for the Immunology Managed Healthcare Marketing team (Humira, pipeline) for AbbVie RFP by working cross functionally with Creative and Account teams, enabling Mosaic to win the contract and become AbbVie managed markets AOR • Assisted in the development of the strategic response to AbbVie RFP by developing a strategy to educate self-funded employers on the potential health dangers of its employees selecting high deductible health plans, helping the Mosaic team win the contract to become AbbVie employer marketing Agency of Record • Created strategic marketing plan in Alkermes RFP response by addressing market access hurdles for patient treatment pathways, winning AOR for both Vivitrol and Aristada managed markets marketing teams• Provided ongoing strategic support to Shingrix pre-launch planning after developing strategic marketing plan for GSK that helped Mosaic become AOR for GSK• Supported brand planning for Janssen Therapeutics HIV portfolio (Prezcobix and pipeline) that educated physicians, hospitals and plans on market insights and trends in HIV treatment, paving the way for a successful product launch

Recruited to create educational tools on all recent reforms in healthcare including Medicare, 340b, Commercial, and Medicaid reforms, quality measures, reimbursement, new payment models, and other aspects of ACA implementation and drive new and existing business by developing successful strategy, tactics, and content to meet specific client needs. • Created client marketing materials on diverse topics as, oncology, HIV/AIDS, neurology, pulmonology, rheumatology, cardiovascular disease and orphan drugs for target audiences such as payers, patients, physicians, and hospital executives• Developed 30+ page brochure for JNJ’s national campaign to improve transitions of care for schizophrenia population post hospitalization, resulting in improved patient care, reduced rates of re-hospitalization, etc., gaining endorsement by National Transitions of Care Coalition • Produced a prelaunch, non-branded tool for Sanofi to be used with payers to increase disease state awareness and provide guidance on ways to better manage an orphan drug population as part of an overall prelaunch payer strategy

Promoted to newly developed position to drive optimal product coverage and payment / reimbursement within Medicaid segment by leading development of portfolio, brand, Medicaid, and business unit strategy / tactics. Partnered with senior executives and staff across corporate divisions to integrate Medicaid market strategies, formulate aggressive corporate policy, and foster internal collaborations. Motivated 15 national / regional account managers through four-person State Account leadership team. Managed $2M annual budget. Supported product sales across all sales divisions and product lines in multiple sclerosis, female health, diagnostic imaging, and oncology by initiating and coordinating state and Medicaid activities including new product launches into Medicaid FSS market place. Called on State of New Jersey, and Wellcare Managed Care, PBM, Medicare, and Managed Medicaid business. Promoted from Associate Director in February 2011.Selected accomplishments: ♦ Achieved 100% PDL inclusion and maintained unrestricted access for Betaseron by recruiting KOL from national MS society and a MSL team liaison to testify at P&T meetings, formulating a contracting strategy with marketing buy-in, and negotiating contracts with key decision makers.♦ Grew sales 3% for Mirena in Medicaid segment despite 40% price increase by developing independent third-party, formulating a non-branded HEOR review of the advantages of contraception, and composing educational memos sent to States defining true cost implications via the MDRP. ♦ Spearheaded rapid uptake for Regorafinib in 100% of States within 6 months of launch by persuading key decision makers to conduct manual system overrides vs. 30-45 days. ♦ Increased sales 10% every year in Medicaid Fee for Service (FFS) markets nationally by developing corporate strategies in response to industry and legislative initiatives.♦ Freed up $80 million in capital by reducing accrual rates of Medicaid managed care rebate reserves.

Chosen to lead reorganization of department, which encompassed creating new roles to address challenges in the entire portfolio and pipeline products and devise and execute appropriate access, reimbursement, and pricing strategies, pricing, and sales estimates. Leveraged market insights to develop and implement coding and pricing strategies in conjunction with brand leads. Led team of seven lobbyists to support product coverage in Medicaid population and regulatory changes impacting PDL coverage. Managed $4M annual budget. Key accounts included State of New Jersey and WellCare. Served on MICAA and AQI Boards of Directors, and PhRMA State Section.Selected accomplishments: ♦ Increased patient support and compliance 11% by migrating Betaseron from open distribution to HUB and Spoke distribution model as an integral team member. ♦ Recovered several million dollars in Medicare reimbursements for Leukine for physicians by co-developing strategy and presenting data to CMS, which resulted in amendment of policy to allow for separate payment for bundled drug.♦ Achieved parity / advantageous access for Betaseron in newly developed Medicare Part D program by developing contracting strategy.♦ Realized 41% market share vs nation at 17% for Betaseron by securing preferred position as sole MS agent in the Wellcare Medicaid program.♦ Spearheaded reorganization of department to allow for long-term growth and align with future portfolio changes, which resulted in adoption across all US and Global development projects and best-in-class status within the Bayer group.♦ Selected as a member of the BU Marketing Leadership Committee and Brand Planning Committees for all 5 divisions.

Recruited to lead development, implementation, and management of Managed Markets strategy. Developed performance analytics, set product goals, and collaborated with marketing and sales counterparts to calculate revised contracting guidelines and pull-through programs. Provided corporate field staff and regional directors with continual research support by integrating customer performance with market trend data. Enabled sales and marketing teams to formulate operational adjustments as product uptake increased by writing and distributing quarterly managed care segments reports.Selected accomplishments: ♦ Achieved 90%+ formulary coverage, Tier 2 inclusion, and preferred product status within 6 months of developing and deploying Managed Markets launch strategy for Yasmin and Betapace AF. ♦ Attained 98% formulary coverage for Betapace AF following launch by developing both Managed Markets launch strategy and pricing.♦ Generated 11% increase in Betaseron sales, and created greater patient access by broadening distribution network from closed / single source to open distribution and developing / negotiating first contract. ♦ Realized 38% market share for Finevin following development of initial launch pricing strategy. ♦ Contributed to the vetting and selection of 3 Market Segment Directors to Regional Account Manager positions.♦ Honored with 2 Creativity Intelligence Teamwork Expertise (CITE) awards for Yasmin launch project and Betaseron distribution change.

Promoted after 2 years from Staff Pharmacist and Pharmacy Supervisor / Union President to direct formulary management, compliance, and contracting functions. Reviewed and recommended ophthalmology and biotech products approved for NPA national formulary as voting member of Pharmacy and Therapeutics Committee. Managed all aspects of generic contracting and purchasing for mail service pharmacy, including direct manufacturer rebate negotiations. Led team of 15 direct reports.Selected accomplishments: ♦ Generated 13% increase in first-year profits with generic volume growing to 2 million prescriptions and $200 million in annual sales.♦ Lowered patient and employer costs 3-4% overall, drove product market share growth, and improved compliance by creating dedicated formulary intervention and compliance departments. ♦ Raised patient compliance rates from 67% to 75% by designing and establishing Multiple Sclerosis patient assistance and support program. ♦ Saved 1.2% annually by negotiating Primary / Secondary wholesale supplier contracts to manage costs in increasingly competitive environment.